We recently met Ajanta Pharma's (AJP) management to get updates on its business segments. Rejigged strategies by the company in a favorable business environment have started yielding results in Asia, while its enhanced focus on Anglo Africa is expected to support growth in Africa???s branded generics business. AJP has also re-strategized to improve growth in dermatology in the domestic formulations segment, and remains on track to outperform industry. We maintain our estimates and re-iterate our Buy rating, with a price target of INR1,840, driven by superior execution in branded generics and a robust product pipeline for the US market.